Deuterated Water Labeling in Ibrutinib-treated Patients with CLL: Leukemia Cell Kinetics Correlate with IGHV, ZAP-70, and MRD

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2024 Oct 23

PMID 39441901

Authors

Ekaterina Kim

Shih-Shih Chen

Mariela Sivina

Hyunsoo Hwang

Xuelin Huang

Alessandra Ferrajoli

Nitin Jain

William G Wierda

Dominik Wodarz

Nicholas Chiorazzi

Jan A Burger

Affiliations

Soon will be listed here.

Abstract

Deuterated ("heavy") water labeling in patients with chronic lymphocytic leukemia (CLL) demonstrates that IGHV unmutated and ZAP-70+ patients have higher blood and tissue CLL death rates on ibrutinib therapy, resulting in lower measurable residual disease levels with long-term ibrutinib treatment. This trial was registered at www.clinicaltrials.gov as #NCT01752426.

References

Admirand J, Rassidakis G, Abruzzo L, Valbuena J, Jones D, Medeiros L . Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol. 2004; 17(8):954-61. DOI: 10.1038/modpathol.3800145. View

Wodarz D, Garg N, Komarova N, Benjamini O, Keating M, Wierda W . Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014; 123(26):4132-5. PMC: 4123432. DOI: 10.1182/blood-2014-02-554220. View

Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View

Rawstron A, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder J . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5):956-64. DOI: 10.1038/sj.leu.2404584. View

Niemann C, Munir T, Moreno C, Owen C, Follows G, Benjamini O . Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023; 24(12):1423-1433. DOI: 10.1016/S1470-2045(23)00452-7. View

Messmer B, Messmer D, Allen S, Kolitz J, Kudalkar P, Cesar D . In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest. 2005; 115(3):755-64. PMC: 548318. DOI: 10.1172/JCI23409. View

Burger J . Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020; 383(5):460-473. DOI: 10.1056/NEJMra1908213. View

Munir T, Cairns D, Bloor A, Allsup D, Cwynarski K, Pettitt A . Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. N Engl J Med. 2023; 390(4):326-337. DOI: 10.1056/NEJMoa2310063. View

Murphy E, Neuberg D, Rassenti L, Hayes G, Redd R, Emson C . Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017; 31(6):1348-1354. PMC: 5462857. DOI: 10.1038/leu.2017.34. View

10.

Packham G, Krysov S, Allen A, Savelyeva N, Steele A, Forconi F . The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. Haematologica. 2014; 99(7):1138-48. PMC: 4077074. DOI: 10.3324/haematol.2013.098384. View

11.

Rassenti L, Huynh L, Toy T, Chen L, Keating M, Gribben J . ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351(9):893-901. DOI: 10.1056/NEJMoa040857. View

12.

Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink A, Robrecht S . Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020; 21(9):1188-1200. DOI: 10.1016/S1470-2045(20)30443-5. View

13.

Hamblin T, Davis Z, Gardiner A, Oscier D, Stevenson F . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6):1848-54. View

14.

Burger J, Wiestner A . Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nat Rev Cancer. 2018; 18(3):148-167. DOI: 10.1038/nrc.2017.121. View

15.

Chen L, Huynh L, Apgar J, Tang L, Rassenti L, Weiss A . ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood. 2007; 111(5):2685-92. PMC: 2254551. DOI: 10.1182/blood-2006-12-062265. View

16.

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

17.

Ten Hacken E, Sivina M, Kim E, OBrien S, Wierda W, Ferrajoli A . Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016; 197(6):2522-31. PMC: 5010921. DOI: 10.4049/jimmunol.1600915. View

18.

Tam C, Allan J, Siddiqi T, Kipps T, Jacobs R, Opat S . Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022; 139(22):3278-3289. PMC: 11022982. DOI: 10.1182/blood.2021014488. View

19.

DAvola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M . Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016; 128(6):816-26. DOI: 10.1182/blood-2016-03-707786. View

20.

Burger J, Barr P, Robak T, Owen C, Ghia P, Tedeschi A . Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2019; 34(3):787-798. PMC: 7214263. DOI: 10.1038/s41375-019-0602-x. View